Lamei Pharmaceuticals has incurred nearly 900 million yuan in losses over seven years: the old growth model has slowed down, and the innovation transformation is still in a painful adjustment period.

After seven consecutive years of losses, with cumulative losses approaching 900 million yuan, Laimei Pharmaceutical’s latest financial report has once again brought this once-specialized pharmaceutical company into the spotlight. In 2025, the company achieved operating revenue of approximately 776 million yuan, with a net profit loss attributable to the parent company of about 135 million yuan, and operational cash flow has significantly weakened. The question facing investors is no longer “when will it turn a profit,” but whether this company can escape the long-term quagmire of its old model losing steam while the new model has yet to establish itself.

01 Cumulative losses nearing 900 million over seven years, blood generation capacity continues to weaken

From 2019 to 2025, Laimei Pharmaceutical’s net profit attributable to the parent company was -155 million yuan, -327 million yuan, -101 million yuan, -68.71 million yuan, -8.927 million yuan, -8.78 million yuan, and -135 million yuan, with cumulative losses nearing 900 million yuan over seven years. More concerning is that the operating cash flow in 2025 plummeted, indicating that the pressure is not only reflected in the accounting losses but also in the continuous decline of the main business’s “blood generation” capacity.

For a pharmaceutical company, this situation means that the traditional business segment is under pressure from multiple fronts, including centralized procurement, price competition, and cost control on the hospital side. Although sales may not have dropped significantly, both unit prices and gross profit margins continue to decline, while innovative R&D typically involves high investment, long cycles, and low certainty. Funds are spent upfront, but results are far from the payout period. Laimei Pharmaceutical finds itself caught between the “old growth model losing steam” and the “new growth model yet to take over.”

02 Business structure under pressure: reliance on single products and coexistence of low-margin businesses

From a business structure perspective, Laimei Pharmaceutical’s core issue lies in the overlapping structural pressures. Pharmaceutical manufacturing, as the traditional main business, continues to be impacted by centralized procurement price shocks; while specialized products have higher gross margins, there is excessive reliance on the core single product—Canalin (nanocarbon suspension injection); the large-volume infusion business relies on winning bids to “exchange price for volume,” but scale expansion has not brought substantial profits; although the pharmaceutical distribution business is growing rapidly, its gross margins are generally low, serving more as a supplementary income rather than improving profitability.

This creates a typical dilemma: revenue has not experienced a cliff-like decline, but profits, cash flow, and asset quality are all under pressure. In the 2025 financial report, further impairment provisions eroded profits, indicating that the company has yet to establish a truly stable new profit model.

03 Core single product Canalin: existence of barriers and reliance

Canalin, as Laimei Pharmaceutical’s most core product, is a lymphatic tracer agent primarily used in surgeries for thyroid cancer, gastric cancer, breast cancer, and colorectal cancer for lymphatic clearance and localization. Its clinical value lies in helping doctors improve surgical localization efficiency and reduce the risk of harming normal tissues, especially in thyroid surgeries where recognizing and protecting the parathyroid glands has significant value.

Due to the special product attributes, Canalin is not easily replaced by generic infusion products, possessing certain clinical scenario barriers. However, the problem is that the company is overly reliant on this single product, and further exploration of indications beyond the thyroid is still needed. If Canalin’s growth potential is limited, the company’s overall profitability will be directly impacted.

04 Innovative pipeline: cutting-edge but high-risk, continuously eroding profits

Laimei Pharmaceutical’s future imagination primarily revolves around extending products from the nanocarbon platform, such as nanocarbon iron suspension injections, with goals expanding from “lymphatic tracing” to lymphatic targeted therapy and broader anti-tumor applications. Additionally, the associated company has also ventured into cutting-edge areas like personalized tumor vaccines and macrophage therapy.

However, the more cutting-edge it is, the more it implies high investment, high risk, and long cycles. One of the significant reasons for the erosion of the company’s profits in recent years has been the accumulation of R&D expenditures, impairment of intangible assets, and losses from joint ventures. For Laimei Pharmaceutical, which is currently not very large, this “transformation tuition” seems particularly heavy.

Summary: The next two to three years is a test of patience

Laimei Pharmaceutical does have trump cards. Canalin proves that the company has the capability to create differentiated products, and the extended layout around the nanocarbon platform represents a certain technological direction. However, the problem is that the company has failed in recent years to organically connect academic value, clinical value, and commercialization capability.

In the next two to three years, Laimei Pharmaceutical will face a test of patience: if the core product can stabilize its fundamentals and the innovation platform can succeed, the company still has room for recovery; if the main business continues to shrink and innovation takes too long to materialize, the current period of pain may be prolonged indefinitely. For investors, the key is not how grand the story is told, but whether clinical value and commercialization capability can truly be realized.

This article is generated in combination with AI tools.